Once-Weekly Semaglutide in Adults with Overweight or Obesity

Abstract

In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight. (Funded by Novo Nordisk; STEP 1 ClinicalTrials.gov number, NCT03548935).

Keywords

SemaglutideObesityOverweightMedicineWeight lossIntervention (counseling)Internal medicineEndocrinologyDiabetes mellitusType 2 diabetesPsychiatry

Affiliated Institutions

Related Publications

Prevalence and determinants of fatty liver in normal-weight and overweight young adults. The Cardiovascular Risk in Young Finns Study

Emmi Suomela , Mervi Oikonen , Johanna Virtanen +15 more

Prevalence of fatty liver was 29% in overweight/obese and 5% in normal-weight adults. Differences in factors associated with fatty liver were seen between these two groups: alco...

2014 Annals of Medicine 46 citations

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

James Larkin , Vanna Chiarion‐Sileni , René González +28 more

BACKGROUND Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advance...

2019 New England Journal of Medicine 3500 citations

Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors’ Expert Forum

William T. Cefalu , John B. Buse , Jaakko Tuomilehto +8 more

The International Diabetes Federation estimates that 415 million adults worldwide now have diabetes and 318 million have impaired glucose tolerance. These numbers are expected t...

2016 Diabetes Care 144 citations

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone

Brent A. Neuschwander‐Tetri

Insulin resistance (IR) commonly is associated with nonalcoholic steatohepatitis (NASH). To establish whether IR causes NASH, this study was undertaken to determine if improving...

2003 Hepatology 699 citations

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis† ‡

Kittichai Promrat , Glen Lutchman , Gabriel I. Uwaifo +11 more

Nonalcoholic steatohepatitis (NASH) is a common chronic liver disease for which there is no known effective therapy. A proportion of patients with NASH progress to advanced fibr...

2004 Hepatology 723 citations

Publication Info

Year: 2021
Type: article
Volume: 384
Issue: 11
Pages: 989-1002
Citations: 3574
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Once-Weekly Semaglutide in Adults with Overweight or Obesity

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

3574

OpenAlex

Cite This

APA Style

                            
                                
                                    John Wilding, 
                                
                                    Rachel L. Batterham, 
                                
                                    Salvatore Calanna
                                
                                et al.
                            
                            (2021). 
                            Once-Weekly Semaglutide in Adults with Overweight or Obesity. 
                            New England Journal of Medicine
                            , 384
                            (11)
                            , 989-1002.
                            https://doi.org/10.1056/nejmoa2032183
                        

Identifiers

DOI: 10.1056/nejmoa2032183